

Patent Selections:

The patents annotated in this section have been selected from various patent collections. They are recent patents categorized by therapeutic area/agent/target and therapeutic agents related to cardiovascular drug discovery and are relevant to the articles published in this journal issue.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

1. Hammock, B.D., Kim, I.-H., Morisseau, C., Watanabe, T., Newman, J.W. Inhibitors for the soluble epoxide hydrolase *US2005016495A1* (2005) and *US20050026844A1* (2005).
2. Ingraham, R.H., Proudfoot, J.R. Methods of using soluble epoxide hydrolase inhibitors *US6890925* (2005).
3. Adams, J.L., Hall, R.F., Boehm, J.C. Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines *US6861417* (2005).
4. Adams, J.L. Substituted imidazole compounds *US6858617* (2005).
5. Cordingley, M.G. Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome P450, such as protease inhibitors *EP1575595A1* (2005).
6. Erlanson, D.A., Braisted, A.C., McDowell, R., Prescott, J. Extended tethering approach for rapid identification of ligands *US6919178* (2005).

STEROL ABSORPTION INHIBITOR

1. Cho, W.-K.P. Methods for inhibiting sterol absorption *US20050153952A1* (2005).
2. Graziano, M.P. Combinations of lipid modulating agents and substituted azetidines and treatments for vascular conditions) *WO05046797A1* (2005) and *WO05046797A2* (2005).
3. Kosoglou, T., Davis, H.R., Picard, G.J.B. Combinations of peroxisome proliferator-activated receptor (PPAR) activators (s) and sterol absorption inhibitors (s) and treatments for vascular indications *NZ0532905A* (2005).
4. Barberich, T.J. Combinations comprising (S)-amlodipine and a HMG-CoA reductase inhibitor or cholesterol absorption inhibitor or both, and methods for reducing hypertension *WO05097191A2* (2005).
5. Bandi P.R., Kura R.R., Rapolu R.R., Dasari M.R., Kesireddy S.C.R.A novel process for ezetimibe intermediate *AU3282384AA* (2005).
6. Sundaram, V., Rajan, S.T., Ramayya, V.P., Vardhan, S.V., Subrahmanyam, B., Sasikala, C.V.A., Polymorphs of ezetimibe and process for preparation thereof *US20050171080A1* (2005).
7. Glombik, H., Frick, W., Schaefer, H.-L., Kramer, W. Pharmaceuticals containing 1, 4-benzothiepine-1, 1-dioxide derivatives and another active substances such as ezetimibe, pamaqueside or tiqueside for treating lipid metabolism and atherosclerotic disorders *NZ0531293A* (2005).

8. Schaffner, C.P., Solomon, K.R., Freeman, M.R. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors *EP1545479A2* (2005).
9. Kumar, Y., Meeran, H.N.P N., Singh, S.K., Rathod, P.D., Ganagakhedkar, K.K., Bose, P., Kumar, P. Process for asymmetric synthesis of hydroxy-alkyl substituted azetidione derivatives of intermediates thereof *WO05066120A2* (2005).
10. Kino, K., Ioriya, K. Medicinal compositions and combinations *WO05058316A1* (2005).
11. Glombik, H., Frick, W., Schaefer, H.-L., Kramer, W. Combination products of aryl-substituted propanolamine derivatives with other active ingredients and the use thereof *NZ0531292A* (2005).
12. Jain, R., Jindal, K.C., Singh, S. Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof *WO05067903A1* (2005).
13. Sundaram, V., Rajan, S.T., Ramayya, V.P., Vardhan, S.V., Subrahmanyam, B., Sasikala, C.V.A. Polymorphs of ezetimibe and processes for the preparation thereof *WO05062897A2* (2005).
14. Parthasaradhi R.B., Rathnakar R.K., Raji R.R., Muralidhara R.D., Subash C.K. A novel process for ezetimibe intermediate *WO05049592A1* (2005).
15. Parthasaradhi R., Rathnakar R.K., Raji R.R., Muralidhara R.D., Subash C.R.K. Ezetimibe polymorphs *WO05009955A1* (2005).
16. Schaffner, C.P., Solomon, K.R. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors *US20050209167A1* (2005).
17. Rapolu R.R., Dasari M.R., Kesireddy S.C., Bandi P.R., Kura R.R. Ezetimibe polymorphs *AU3259547AA* (2005).
18. Kosoglou, T., Ress, R.J., Strony, J., Veltri, E.P., Hauer, W. Combinations of sterol absorption inhibitor (s) with cardiovascular agent (s) for the treatment of vascular conditions *EP1541175A2* (2005) and *CN1582168A* (2005).

SYMPATHOLYTIC CARDIOVASCULAR AGENT

1. Hildebrand, K.R., Ujhelyi, M.R., Zhou, X., Sigg, D.C., Page, L.M., Delivery of a sympatholytic cardiovascular agent to the central nervous system *US20050177097A1* (2005).

- Hildebrand, K., R., Ujhelyi, M.R., Zhou, X., Sigg., D.C., Page, L.M. Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure *WO05077439A1* and *US20050177135A1* (2005).

CARDIOVASCULAR AGENTS

- Christodoulou, D.D., Wink, D.A. Jr., Keefer, L.K. Mixed Ligand Metal Complexes of Nitric Oxide-Nucleophile Adducts useful as Cardiovascular Agents *CA2132847C* (2005).
- Carson, J.R., Lee, J.S. 3- (Diheteroaryl)methylene)-8-Azabicyclo[3.2.1]Octane and 3- (Aryl) (Heteroaryl) Methylene)-8-Azabicyclo[3.2.1]Octane Derivatives *WO05075472A1* (2005).
- Carson, J.R., Lee, J.S. 3- (diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl) (heteroaryl) methylene)-8-azabicyclo[3.2.1]octane derivatives *US20050171099A1* (2005).
- Coats, S.J., Carson, J.R., Neilson, L.A., Pitis, P.M., Schulz, M.J. 3- (diarylmethylene)-8- azabicyclo [3.2.1] octane derivatives *US20050004163A1* (2005).
- Tracey, R., W. Compounds for Treatment of Cardiovascular Diseases *WO05079803A1* (2005).

ANTITHROMBOTIC AND ANTICOAGULANT

- Stocker, A., Preston, J., Rayner, J.W., Smithers, M.J., Turner, P., Heterocyclic derivatives *US6936610* (2005).

BENZAMIDINE DERIVATIVES

- Baxter, E.W., Nortey, S.O., Reitz, A.B., Benzamide derivatives *US6887876* (2005).

CALCIUM CHANNEL BLOCKER

- Moon, Y.-H., Kim, N.-D., Lee K.-I., Lee, G.-S., Woo, J.- S., Novel amlodipine camsylate and method for preparing thereof *NZ0528362A* (2005).

AT1-RECEPTOR ANTAGONIST AND A CARDIOVASCULAR AGENT

- Buhlmayer P., Webb R.L., Salts formed of an AT1-receptor antagonist and a cardiovascular agent *CN1571668A* (2005).

PYRAZOLINES AS PAR-1 ANTAGONISTS

- Allerheiligen, S., Brohm, D., Diedrichs, N., Fröhlen, B.-N., Gerdes, C., Gnoth, M.J., Heckroth, H., Hübsch, W., Perzborn, E. Pyrazolines as PAR-1 Antagonists for Treatment of Cardiovascular Diseases *WO05007157A1* (2005).

APOLIPOPROTEIN ANALOGUES

- Graversen, J., Moestrup, S., Method of producing apolipoprotein analogues *US20050142639A1* (2005).
- Graversen, J., Moestrup, S., Methods of prevention and treatment using apolipoprotein analogues *US20050096277A1* (2005).

- Graversen, J., Moestrup, S., *US6897039* (2005) Apolipoprotein analogues.

GLYCOGEN PHOSPHORYLASE INHIBITORS

- Rytved, K.A., Dragsted, N., Nyborg, N.C.B., Iversen, L., Kristiansen, M. Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases *US20050054618A1* (2005).
- Rytved, K.A., Dragsted, N., Nyborg, N.C.B., Iversen, L., Kristiansen, M., Use of Glycogen Phosphorylase Inhibitors for Treatment of Cardiovascular Diseases *EP1558245A2* (2005).

ARRHYTHMIA

- Wolff, A.A. Sustained release ranolazine formulations *US6852724* (2005).

ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST

- Subhash D., Barbara R., John C.A., Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease *AU5201045AA* (2005).
- Riedel, A., Leiter, J.M.E., Sendra, J.-M., Kauschke, S., Mark, M., Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases *US20050004193A1* (2005).

ANGIOTENSIN II RECEPTOR ANTAGONISTS

- Kauschke, S., Mark, M., Kintscher, U., Schupp, M., Unger, T. Use of angiotensin II receptor antagonists, especially telmisartan, in order to increase insulin sensitivity *WO05011680A1* (2005).
- Almirante, N., Del Soldato, P., Ongini, E. Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases *WO05011646A3* (2005).

TELMISARTAN

- Davidai, G. Use of telmisartan for the prevention of vascular headache) and *US20050065094A1* (2005).
- Kohlrausch, A., Multilayer tablet *US20050186274A1* (2005) and *WO05079762A1* (2005).
- Friedl, T., Schepky, G. Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof *US20050089575A1* (2005) and *BG0108781A* (2005).
- Nakatani, M., Ohki, T., Takeshi, S., Toyoshima, K. Solid pharmaceutical formulations comprising telmisartan *EP1545467A1* (2005).
- Kauschke, S., Mark, M. Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis *DE10335027A1* (2005).

- Montgomery, H.E., Martin, J.F., Erusalimsky, J.D. The use of inhibitors of the renin-angiotensin system) *EPI498124A3 (2005)* and *EPI498124A2 (2005)*.

AGEs AND RAGE

- Shahbaz, M. M. Methods to identify compounds that modulate RAGE *US6908741 (2005)*.
- Morré, D.M., Morré, D.J. Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof *US6878514 (2005)*.
- Schäfer, S.W., Linz W., Bleich, M., Huber, J. Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases *US6930103 (2005)*.

PPAR-

- Clary, L., Collette, P., Rivier, M., Jomard, A. Compounds which modulate PPAR & gamma; type receptors, and use thereof in cosmetic or pharmaceutical compositions *EPI572629A1 (2005)*.
- Amemiya, Y., Wakabayashi, K., Takaishi, S., Fukuda, C. PPAR (gamma) modulators *EPI277729A4 (2005)*.
- Binggeli, A., Boehringer, M., Grether, U., Hilpert, H., Maerki, H.-P., Meyer, M., Mohr, P., Ricklin, F. Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes *NZ0529033A (2005)*.
- Amano, Y., Sugiyama, Y., Nishida, M., Taketomi, S. Disease model animal carrying foreign PPARA gene transferred thereinto and use thereof *EPI535512A1 (2005)*.
- Nomura, M., Takahashi, Y., Tanase, T., Miyachi, H., Tsunoda, M., Ide, T., Murakami, K. Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) *EPI1184366B1 (2005)*.
- Pinsky, D., Collins, T. Inhibition of egr-1 expression by PPAR- agonists and related compositions and methods *WO05000196A3 (2005)* and *WO05000196A2 (2005)*.
- Fu, J., Gaetani, S., Piomelli, D. Compounds, compositions and therapeutic uses of oleoylethanolamide-like compounds and modulators of PPAR- . *WO05002524A3 (2005)* and *WO05002524A2 (2005)*.
- Kim, G.T., Koh, J.S., Han, H.O., Kim, S.H., Kim, K.-H., Chung, H.-K., Kim, Y.C., Kim, M., Koo, K.D., Yim, H.J., Hur, G.-C., Lee, S.H., Lee, C.-S., Woo, S.H. Novel compounds as agonist for PPAR gamma and PPAR alpha, method for preparation of the same, and pharmaceutical composition containing the same *WO05040127A1 (2005)*.
- Phipps, R.P., Sime, P.J., Blumberg, N. Use of peroxisome proliferator-activated receptor gamma (PPAR) and/or retinoic acid receptor (RXR) agonists to inhibit platelet functions *WO05041872A2 (2005)*.

CARDIAC REMODELING

- Rosen, M.R., Peters, N.S., Palti, Y. Cardiac remodeling *US6868287 (2005)*.

UNREGULATED ANGIOGENESIS AND/OR VASCULOGENESIS

- Tang, P.C., Sun, L., Shawver, L.K., Hirth, K.P., Fong, A. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis *US6846839 (2005)*.

BLOOD VESSEL LIPID DEPOSITION – PREVENTIVE AGENT

- Fukami, H., Urata, H. Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor *US6921766 (2005)*.

XANTHINE PHOSPHODIESTERASE V INHIBITORS

- Chackalamannil, S., Wang, Y., Boyle, C.D., Stamford, A.W. Xanthine phosphodiesterase V inhibitors *US6821978 (2005)*.
- Chackalamannil, S., Wang, Y., Boyle, C.D., Stamford, A.W. Xanthine phosphodiesterase V inhibitors *US6894040 (2005)*.
- Blizzard, T.A., Gude, C., Morgan, J.D., II Estrogen Receptor Modulators *WO05051972A1 (2005)*.
- Feldman, D.L., Webb, R.L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic *US20050182042A1 (2005)*.

VASCULAR DISORDERS AND HYPERTENSION

- Endou, H., Kanai, Y., Johnson, R.J., Price, K.L. Remedy/preventive for vascular disorders and hypertension and method of screening the same *WO05046724A1 (2005)*.
- Shimkets, R.A., Lowe, D.G. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis *US6875567 (2005)*.
- Beq, F., Robert, R., Pignoux, L., Rogier, C., Mettey, Y., Vierfond, J.M., Joffre, M., Marivingt-Mounir, C. Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction *US20050176747A1 (2005)*.
- Calder, P., Grimble, R., Gallagher, P., Shearman, C. Use of EPA and DHA in secondary prevention *US20050171200A1 (2005)*.

INHIBITING SMOOTH MUSCLE CELL CONTRACTION

- Ivanov, V., Ivanova, S., Roomi, W.M., Niedzwiecki, A., Rath, M. Nutritional composition and method of inhibiting smooth muscle cell contraction thereof *US20050019429A1 (2005)*.
- Härter, M., Hahn, M., Hirth-Dietrich, C., Knorr, A., Stahl, E., Stasch, J.-P., Wunder, F. Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases *US6939989 (2005)*.

ANTITHROMBOGENIC MEMBRANE MIMETIC COMPOSITIONS

1. Chaikof, E.L., Feng, J., Orban, J.M., Liu, H., Sun, X.-L. Antithrombogenic membrane mimetic compositions and methods *US6936298 (2005)*.

HYPERPROLIFERATIVE DISORDERS

1. Rosen, C.A., Haseltine, W.A. Albumin fusion proteins *US6926898 (2005)* and *US6905688 (2005)*.

EP4 RECEPTOR

1. Giblin, G.M.P., Jones, H.T., Mason, A.M., Miller, N.D., Roomans, S., Shanahan, S.E., Walker, A.L. Naphthalene derivatives which bind to the EP4 receptor *US6924297 (2005)*.

ISCHAEMIC INJURY, HYPERTENSION, ANGINA, REPERFUSION INJURY OR INFLAMMATION

1. Stamler, J.S. No-modified hemoglobins and uses therefore *US6911427 (2005)*.
2. Stamler, J.S. Methods for producing and using S-nitrosohemoglobins *US6855691 (2005)*.
3. Pullela, P.K., Rangappa, P., Alapati, S.R., Subbarao, P.V., Bibbs, J.A. 1, 4-dihydropyridine and pyridine compounds as calcium channel blockers *US6852742 (2005)*.
4. Bergeron, Jr. R.J. Anti-hypertensive composition and methods of treatment *US6841576 (2005)*.
5. Schnidler, U., Schoenafinger, K., Strobel, H. Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same *US6844347 (2005)*.

ATHEROSCLEROSIS, HYPERTENSION, SVAS OR OTHER VASCULAR DISEASE

1. Keating, M.T., Li, D.Y. Mice which are +/- or -/- for the elastin gene as models for vascular disease *US6903244 (2005)*.
2. Termin, P.L., Carr, R.M. Jr., Condon, K.D. Method for treating diseased or damaged organs *US6890351 (2005)*.

SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES

1. Schindler, U., Schönafinger, K., Strobel, H. Sulfur substituted sulfonylamino-carboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them *US6881735 (2005)*.

MYOCARDIAL INFARCT

1. DeLong, M.A. 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use *US6894175 (2005)*.

HUMAN LEUKOCYTE 12-LIPOXYGENASE

1. Nadler, J.L., Natarajan, R. Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states *US6893829 (2005)*.

ANTIPLATELET AGGREGATION AGENTS

1. Chen, I.-J. KMST isoeugenol Derivatives and Pharmaceutical Activity *US6887878 (2005)*.

HISTAMINE H3 RECEPTOR AGONIST

1. Levi, R., Silver, R.B. Method and compositions for reducing cardiac dysfunctions with a selective histamine H3 receptor agonist *US6884809 (2005)*.

DIABETIC RETINOPATHY

1. Anaclerio, B.M., Marugan S.J.J., Marder, V.J., U'Prichard, D.C., Tomczuk, B.E. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists *US6872730 (2005)*.
2. Lu, T., LaFrance, L.V., Markotan, T.P., Marugan S.J.J., Marder, V.J., U'Prichard, D.C., Anaclerio, B.M., Guo, Z., Pan, W., Leonard, K.A., Tomczuk, B.E. Substituted indoles and their use as integrin antagonists *US6855722 (2005)*.

ADIPSIN/COMPLEMENT FACTOR D

1. Lucas, J., Briggs, K. Use of adipsin/complement factor D in the treatment of metabolic related disorders *US6867189 (2005)*.

CARDIAC HYPERTROPHY

1. Olson, E.N., Nicol, R. Transgenic mice comprising a constitutively-activated MEK5 and exhibiting cardiac hypertrophy and dilated cardiomyopathy *US6924415 (2005)*.
2. Tanizawa, K., Iwata, M., Kuroda, S., Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby *WO05018673A1 (2005)*.
3. Olson, E.N., Lu, J., McKinsey, T., Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression *US20050106654A1 (2005)*.
4. McKinsey, T.A., Olson, E., Harrison, B., Rybkin, I., Helmke, S. Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure *WO05074941A1 (2005)*.
5. Bush, E., Olson, E. Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure and *US20050182011A1 (2005)*.
6. Belmont, J.W., Fletcher, F.A., Chen, A.J., Jurecic, R., Tan, T.-H., Zhou, G. Phosphatases which activate MAP kinase pathways *US6900043 (2005)*.
7. Grant, S.R., Olson, E.N., Molkenin, J.D. Transgenic animal models for cardiac hypertrophy and uses thereof *EP1025216B1 (2005)*.
8. Bush, E., Olson, E., Melvin, L., Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases *WO05063220A1 (2005)*.
9. Bristow, M., Gorczyński, R., Webb, N., Domet, J., Shah, D., Jarosz, P. Enoximone formulations and their

- use in the treatment of cardiac hypertrophy and heart failure *WO05058280A2* (2005).
10. Kihara, Y. Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor *WO05039638A2* and *WO050309638A3* (2005).
 11. Matsui, H., Matsushita, M. Transmembrane NFAT inhibitory peptide *US20050096267A1* (2005).
 12. Kihara, Y., Remedial Agent for Cardiac Failure *EPI1419767A4* (2005).
 13. Bush, E., Melvin, L. 5-HT₂ Receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases *WO05063712A1* (2005).
 14. Sedrani, R., Maibaum, J.K., Breitenstein, W. 4-Phenylpiperidine derivatives as renin inhibitors *WO05051911A1* (2005).
 15. Baeschlin, D.K., Maibaum, J.K., Sellner, H. Organic Compounds *WO05051895A1* (2005).
 16. Fritzeimer, K.-H., Peters, O., Pelzer, T., Neyses, L., Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1, 3, 5 (10)-trien-3, 17beta-diol and 17beta-fluor-9 alpha-vinyl-estra-1, 3, 5 (10)-trien-3, 16alpha-diol *WO05051401A3* (2005).
 17. Hegele-Hartung, C., Fritzeimer, K.-H., Peters, O., Pelzer, T., Neyses, L. Prevention and treatment of hypertensive heart diseases by the selective estrogens 8 beta-vinyl-estra-1, 3, 5 (10)-trien-3, 17beta-diol and 17 beta-fluor-9 alpha-vinyl-estra-1, 3, 5 (10)-trien-3, 16 alpha-diol *WO05051401A2* (2005).
 18. Fritzeimer, K.-H., Hegele-Hartung, C., Neyses, L., Pelzer, T., Peters, O. Prevention and treatment of hypertensive heart diseases by the selective estrogens 8 beta-vinyl-estra-1, 3, 5 (10)-trien-3, 17beta-diol and 17 beta-fluor-9alpha-vinyl-estra-1, 3, 5 (10)-trien-3, 16 alpha-diol *US20050148560A1* (2005).
 19. Spelsberg, T., Subramaniam, M. Transgenic TIEG Non-Human Animals *WO05027625A2* (2005).
 20. Williams, P.M., Gerritsen, M.E. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs *US20050202008A1* (2005).
 21. Sakamoto, A., Desmin gene having novel point mutation causative of dilated cardiomyopathy *US20050155092A1* (2005).
 22. Lee, R.T. Cardiovascular disease diagnostic and therapeutic targets *US20050130136A1* (2005).
 23. Kao, P.N., Pearl, R.G., Nishimura, T., Faul, J.L. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases *US20050119330A1* (2005).
 24. Li, Y., Uskokovic, M. Vitamin D and vitamin D analogs or derivatives as new anti-hypertensive agents *US20050113348A1* (2005).
 25. Schwartz, B., Branellec, D., Chien, K., Chen, J., Benoit, P. Promoter sequences upstream of the carp gene, vectors containing them and uses in treating cardiac disorders *NZ0526408A* (2005).
 26. Finer, J.T., Bergnes, G., Feng, B., Smith, W.W., Chabala, J.C. Methods and compositions utilizing quinazolinones *NZ0530074A* (2005).
 27. Urata, H., HASE, N., Tsuchiya, N. Drugs containing chymase inhibitor and ace inhibitor as the active ingredients *EPI1419785A4* (2005).
 28. Sakamoto, A., Desmin Gene having Novel Point Mutation Causative of Dilated Cardiomyopathy *EPI443111A4* (2005).
 29. Furuishi, T., Minami, K., Minowa, T., Komine, M., Kimura, K., Proline Ester and Preparation containing the same for Percutaneous Administration *EPI538158A1* (2005).
 30. Joly, A., Schreiner, G., F., Stanton, L.W., White, R.T., Damm, D.L., Lewicki, J.A. Methods for detection and use of differentially expressed OSF-2 in diagnosis of cardiac hypertrophy *EPI524524A1* (2005).
 31. Wang, H.U., Chen, Z., Anderson, D.J. Artery- and vein-specific proteins and uses therefore *US6916625* (2005).
 32. Greenberg, A.S. Methods for treating and preventing insulin resistance and related disorders *US6897019* (2005).
 33. Yamashita, D.S., Lin, H., Wang, W. Inhibitors of AKT activity *WO05085227A1* (2005).
 34. Golz, S., Brüggemeier, U., Geerts, A. Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 alpha (GSK3A) *WO05083105A2* (2005).
 35. Green, J., Marhefka, C. Phthalimide compounds useful as protein kinase inhibitors *WO05039564A1* (2005).
 36. Czech, M.P., Jiang, Z.Y. Methods of identifying insulin response modulators and uses therefore *US20050208054A1* (2005).
 37. Nuss, J.M., Ramurthy, S. Pyrazine based inhibitors of glycogen synthase kinase 3 *US6949547* (2005).
 38. Guo, K., Pagnoni, M.F., Clark, K.L., Ivashchenko, Y.D. AKT Nucleic acids, polypeptides, and uses thereof *US6881555* (2005).
 39. Wash, P.L., Wiley, B.M., Hassig, C., Malecha, J.W., Noble, S.A. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease *US20050026907A1* (2005).
- LIVER X RECEPTOR (LXR)ALPHA & BETA SELECTIVE AGONISTS**
1. Schulman, Ira G., Bischoff, E.D., Tangirala, R.K. Methods for affecting various diseases utilizing LXR compounds *US6924311* (2005).

2. Tontonoz, P.J., Joseph, S.B., Castrillo, A. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors *WO05070072A2* (2005).
3. Molteni, V., Li, X., Nanakka, J., Ellis, D.A., Anaclerio, B., Saez, E., Wityak, J. Compounds and compositions as LXR Modulators *WO05077124A2* (2005).
4. Piomelli, D., de Fonseca F.R. Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism *US6911474* (2005).
5. Adams, A.D., Bouffard, A., Dropinski, J.F., Gutteridge, C.E., Jones, A.B., Lui, W., Ondeyka, J.G., Shiafee, A., Singh, S.B. Therapeutic compounds for treating dyslipidemic conditions *US6908934* (2005).
6. Van Camp, J.A., Malecha, J.W., Miyashiro, J.M., DeCrescenzo, G.A., Collins, J.T., Kalman, M.J., Anilino liver X-receptor modulators *US6900244* (2005).
7. Chandrakumar, N.S., Dalton, C.R., Malecha, J.W., Tollefson, M.B., Van Camp, J.A., Cox, P.B. Aromatic liver X-receptor modulators *EP1542966A1* (2005).
8. Boggs, S., Collins, J.L., Fivush, A., Stewart, E.L., Willson, T.M. Purine derivatives SS liver X receptor agonists *EP1521584A1* (2005).
9. Becker, D.P., Decrescenzo, G.A., Malecha, J.W., Miyashiro, J.M., Van Camp, J.A. Collins, J.T. Sulfone liver X-receptor modulators *EP1511723A1* (2005).
10. Van Camp, J.A., Malecha, J.W., Miyashiro, J.M., Decrescenzo, G.A., Collins, J.T., Kalman, M.J. Anilino liver X-receptor modulators *EP1509495A1* (2005).
11. Liao, S., Song, C. Liver X receptor agonists *CN1585777A* (2005).
12. Saez, E., Tontonoz, P., Laffitte, B.A., Li, J. Novel use of liver X receptor agonists *US20050036992A1* (2005).
13. Bayne, C.D., Johnson, A.T., Lu, S.-P., Mohan, R., Nyman, M.C., Schweiger, E.J., Stevens Jr., W., C., Wang, H., Xie, Y. Modulators of LXR *US20050080111A1* (2005).
14. Boström, J., Brickmann, K., Holm, P., Sandberg, P., Swanson, M., Westerlund, C. Pyrrole-2, 5-dione derivatives as liver X receptor modulators *WO05005417A* (2005).
15. Holm, P. Pyrrole-2, 5-Dithione Derivatives as liver X receptor modulator *WO05005416A* (2005).
16. Tontonoz, P., Joseph, S.B., Castrillo, A. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors *US20040259948A1* (2005).
3. Sircar, J., Alisala, K., Nikoulin, I. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia *US20050159362A* (2005).
4. Dasseux, J.-L.H., Oniciu, C.D. Intermediates for the synthesis of ether compounds *US6909014* (2005).
5. Abe, H., Houze, J., Kawasaki, H., Kayser, F., Sharma, R., Sperry, S. Linked biaryl compounds *US6869975* (2005).
6. Fogelman, A.M., Navab, M., Hama, S. Functional assay of high-density lipoprotein *US6869568* (2005).
7. Wright, S.D., Cai, T.-Q. Method for determining the efficacy of reverse cholesterol transport enhancing agents *EP1401456A4* (2005).
8. Staels B. Method for identifying compounds modulating reverse cholesterol transport *CN1568374A* (2005).

CETP INHIBITORS

1. Dalvie, D.K., Ruggeri, R.B., CETP Inhibitors and Metabolites Thereof and *WO05033082A3* (2005).

NITRIC OXIDE SYNTHASE

1. Nunokawa, Y., Suzuki, K., Saitoh, M. NF- κ B inhibitor comprising phenylmethyl benzoquinone as the active ingredient *US6943196* (2005).
2. Bigot, A., Carry, J.-C., M.S. Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase *US6953796* (2005).
3. Pitzele, B.S., Sikorski, J.A., Webber, R.K. 2 - Amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors *US6956131* (2005).
4. Sundermann, C., Sundermann, B., Przewosny, M., Hennies, H.-H. Use of substituted gamma-lactone compounds as pharmaceutical preparations *US6943181* (2005).
5. Henry, M.O., Lynn, W.S. Modulation of cell fates and activities by diketo phthalazines *US6953799* (2005).
6. Strobel, H., Wohlfart, P. Acylated 1, 2, 3, 4-tetrahydronaphthyl amines and their use as pharmaceutical agents *US6949556* (2005).
7. Webber, R.K., Durley, R.C., Awasthi, A.K., Bergmanis, A.A., Fok, K.F., Ganser, S.S., Hagen, T.J., Hallinan, E.A., Hansen, D.W. Jr., Hickory, B.S., Manning, P.T., Mao, M., Moormann, A.E., Pitzele, B.S., Promo, M.A., Schartman, R.R., Scholten, J.A., Snyder, J.S., Toth, M.V., Trivedi, M., Tsymbalov, S., Tjoeng, F.S. Amidino compounds useful as nitric oxide synthase inhibitors *US6914158* (2005).
8. Earl, R.A., Ezawa, M., Fang, X., Garvey, D.S., Gaston, R.D., Khanapure, S.P., Letts, L.G., Lin, C.-E., Ranatunga, R.R., Richardson, S.K., Schroeder, J.D., Stevenson, C.A., Wey, S.-J. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use *US20050222243A1* (2005).
9. Garvey, D.S., De Tejada, I.S., Gaston, R.D., Khanapure, S.P., Shelekhin, T.E., Wang, T. Nitrosated

REVERSE CHOLESTEROL TRANSPORT

1. Fogelman, A.M., Anantharamaiah, G.M. Orally administered peptides to ameliorate atherosclerosis *US6933279* (2005).
2. Fogelman, A.M., Navab, M. G-type Peptides to ameliorate atherosclerosis *US6930085* (2005).

- and nitrosylated alpha-adrenergic receptor antagonist compounds *US2005018722A1 (2005)*.
10. Cheshire, D., Connolly, S., Cox, D., Millichip, I. Use of phenylheteroalkylamine derivatives *US6953797 (2005)*.
 11. Hansen, D.W.Jr., Webber, R.K., Pitzele, B.S., Sikorski, J., Massa, M.A., Hagen, T.J., Grapperhaus, M., Wang, L.J., Bergmanis, A.A., Kramer, S.W., Hallinan, E.A. 2 - Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors *US6951889 (2005)*.
 12. Ponnappalli, M.G., Jeeja, M.M., Venugopalan V.M.V. Novel in-expensive and efficient process for isolation of imperatorin, a potent inducible nitric oxide synthase inhibitor and anti-inflammatory drug candidate from *Aegle marmelos* Correa *US20050220913A1 (2005)*.
 13. Mete, A., Walters, I. Novel compounds *US20050203172A1 (2005)*.
 14. Asberom, T., Clader, J.W., Hu, Y., Pissarnitski, D.A., Stamford, A.W., Xu, R. Polycyclic guanine derivative phosphodiesterase V inhibitors *US6943171 (2005)*.
 15. Niewohner, M., Es-Sayed, M., Haning, H., Schenke, T., Schlemmer, K.-H., Keldenich, J., Bischoff, E., Perzborn, E., Dembowski, K., Serno, P., Nowakowski, M., Niewöhner, U. 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors *US6890922 (2005)*.
 16. Kushner, P., Webb, P., Williard, R., Hunt, C.A., Lopez, G. Methods for screening compounds for estrogenic activity *US6884577 (2005)*.
 17. Bloch, K.D., Ichinose, F., Zapol, W.M. Enhancing therapeutic effectiveness of nitric oxide inhalation *US6935334 (2005)*.
 18. Zapol, W.M., Bloch, K.D., Rosenzweig, A. Use of inhaled NO as anti-inflammatory agent *US6811768 (2004)*.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

1. Treadway, J.L. Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors *US6867184 (2005)*.
2. Fine, S.A., Kinsella, K.J. Compositions and methods for treatment for glucose metabolism disorders *US6852760 (2005)*.

HDL-CHOLESTEROL

1. Tamura, H., Nishino, S., Yamaguchi, T., Hino, K. Test piece for assaying high density lipoprotein (HDL) cholesterol *US6939682 (2005)*.
2. Tajima, H., Nakayama, Y., Tatsumi, T., Fukushima, D. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient *US6924295 (2005)*.
3. Moss, N., Regan, J.R. Methods of treating cytokine mediated diseases *US6916814 (2005)*.

4. DeNinno, M.P., Magnus-Aryitey, G.T., Ruggeri, R.B., Wester, R.T. 4-Carboxyamino-2-substituted-1, 2, 3, 4-tetrahydroquinolines *US6906082 (2005)*.
5. Luchoomun, J., Meng, C.Q., Saxena, U., Sikorski, J.A. Combined cholesterol and bilirubin tests as risk predictors for coronary artery disease *US6869802 (2005)*.
6. Luchoomun, J., Meng, C.Q., Saxena, U., Sikorski, J.A. Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality *US6881860 (2005)*.

LDL-CHOLESTEROL

1. Brown, D., Golub, L.M., Lee, H.-M., Greenwald, R., Ryan, M., Desai, K. Method for decreasing low density lipoprotein *US6841547 (2005)*.
2. Blizzard, T.A., Hammond, M.L., Morgan, J.D., Mosley, R.T. Estrogen receptor modulators *US6838584 (2005)*.

VASOPROTECTION

1. Gebicki, J., Chlopicki, S. The use of quaternary pyridinium salts as vasoprotective agents *WO05067927A2 (2005)*.
2. Blume, G., Teichmüller, D. Combined cosmetic or therapeutic preparation *WO05046623A1 (2005)*.
3. Bombardelli, E. Combinations of vasoprotective agents and formulations containing them *WO05000041A1 (2005)*.

ENDOTHELIAL FUNCTION

1. Maltz, J.S., Budinger, T.F. Arterial endothelial function measurement method and apparatus *WO05079189A2 (2005)*.
2. Cooper, G.J.S., Baker, J.R. Preventing and/or treating cardiovascular disease and/or associated heart failure *US6951890 (2005)*.
3. Tanaka, Y., Yoshimura, T., Izawa, H., Ejima, C., Kojima, M., Satake, Y., Nakanishi, E., Suzuki, N., Makino, S., Suzuki, M., Murata, M. Phenylalanine derivatives *US6855706 (2005)*.

REACTIVE OXYGEN SPECIES

1. Mascarenhas, D. IGF-binding protein-derived peptide or small molecule *US6914049 (2005)*.
2. Baker, J.R., Cooper, G.J.S. Fructosamine oxidase: antagonists and inhibitors *US6897243 (2005)*.
3. Rotta, A.T., Fuhrman, B.P., Gunnerson, B., Steinhorn, D.M., Hernan, L.J. Method for reducing free-radical induced injury *US6894079 (2005)*.
4. Grönberg, A., Wikström, P. Identification of agents that increase glucose uptake *US6893833 (2005)*.
5. Sabbadini, R.A. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefore *US6881546 (2005)*.

6. Mascarenhas, D. IGF-binding protein-derived peptide *US6861406 (2005)*.
7. Sabbadini, R.A. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefore *US6858383 (2005)*.
8. Baker, J.R. Fructosamine oxidase assay: methods and materials *US6855511 (2005)*.

FREE RADICAL SCAVENGER

1. Fridovich, I., Batinic-Haberle, I., Crapo, J.D., Day, B.J. Substituted porphyrins *US6916799 (2005)*.
2. Wolff, A.A. Sustained release ranolazine formulations and *US6852724 (2005)*.

FREE RADICALS AS CARDIOPROTECTIVE AGENTS

1. Mukherjee, R., Singh, A.T., Dutta, K., Maickap, G.C., Shukla, A.K., Khattar, D., Burman, A.C. Cardioprotective agents *US20050020666A1 (2005)*.
2. Malfroy-Camine, B., Baudry, M., Synthetic Catalytic Free Radical Scavengers useful as Antioxidants for Prevention and Therapy of Disease *EP0746321B1 (2005)*.

RESTENOSIS

1. Wiktor, D.M. Intravascular stent *US6923828 (2005)*.
2. Griebenow, N., Flessner, T., Härter, M., Raabe, M., Buchmüller, A., Bischoff, H., Ellinghaus, P., Kolkhof, P. Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases *WO05077907A1 (2005)*.
3. Woltering, E., Härter, M., Flessner, T., Jeske, M., Griebenow, N., Süßmeier, F., Bischoff, H., Raabe, M., Buchmüller, A., Kolkhof, P., Ellinghaus, P., Weber, O. Tricyclic benzazepine derivatives as squalene synthase inhibitors used for the treatment of cardiovascular diseases *WO05068472A1 (2005)*.
4. Ding, N. High-density lipoprotein coated medical devices *WO05068020A1 (2005)*.
5. Daum, W., Foreman, A., Gwost, D.U., Ivkov, R. Therapy via targeted delivery of nanoscale particles *WO05044365A2 (2005)*.
6. Liao, G., Stefansson, S., Su, J. Endothelial cell specifically binding peptides *WO04056080C2 (2005)*.
7. DiNinno, F.P., Blizzard, T.A., Morgan J.D. II Estrogen receptor modulators *US20050234245A1 (2005)*.
8. Hale, M.R., Maltais, F., Tang, Q., Straub, J., Aronov, A. Heterocyclic inhibitors of ERK2 and uses thereof *US20050234059A1 (2005)*.
9. Tang, O., Maltais, F., Janetka, J.W., Hale, M.R. Pyrazole-derived kinase inhibitors and uses thereof *US20050215550A1 (2005)*.
10. Garvey, D.S. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use *US20050209266A1 (2005)*.

11. Honjo, T., Tashiro, K., Kobuke, K. Novel polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide *US20050202481A1 (2005)*.
12. Najib, J., Caumont-Bertrand, K. Composition based on substituted 1, 3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof *US20050171149A1 (2005)*.
13. Dasseux, J.-L., Sekul, R., Buttner, K., Cornut, I., Metz, G., Dufourcq, J. Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders *US20050148513A1 (2005)*.
14. Logan, T.J., Chun, M. Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210 *US20050142604A1 (2005)*.
15. Schreiner, G.F. Stents and intra-luminal prostheses containing map kinase inhibitors *US20050129729A1 (2005)*.
16. Husband, A., Kelly, G.E. Treatment of restenosis *US20050119301A1 (2005)*.
17. Ivkov, R., Daum, W., Foreman, A., Gwost, D. Therapy via targeted delivery of nanoscale particles *US20050090732A1 (2005)*.
18. Hale, M.R., Janetka, J.W., Maltais, F., Cao, J., Mashal, R. Isoxazole compositions useful as inhibitors of ERK *US20050090536A1 (2005)*.
19. Robertson, A.D., Jackson, S., Kenche, V., Yaip, C., Parbaharan, H., Thompson, P. Therapeutic morpholino-substituted compounds *US20050085471A1 (2005)*.
20. Wohlfart, P., Suzuki, T., Dharanipragada, R.M., Safarova, A., Walser, A., Strobel, H. 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical *US20050054729A1 (2005)*.
21. Day, D.E., Link, C.A. Anti-human vitronectin antibody and methods for making the same *US20050048057A1 (2005)*.
22. Ghosal, A., Tong, W., Chowdhury, S.K., Zbaida, S., Wirth, M.A., Alton, K.B., Patrick, J.E., Boyle, C.D., Stamford, A. Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction *US20050026939A1 (2005)*.
23. Stagliano, N.E., Healy, A., Acton, S.L., Galvin, K.M., Donoghue, M.A., Rodrigue-Way, A., Tomlinson, J.E. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, *US20050037946A1 (2005)*.
24. Evans, D.G., Nash, J.E. Transmyocardial revascularization system and method of use *US6955681 (2005)*.

25. Zhu, L., Lalwani, N.D., Dasseux, J.-L. Methods of using non-human animal Apolipoprotein A-I protein *US6953840 (2005)*.
26. Hale, M., Janetka, J., Maltais, F. Pyrazole compositions useful as inhibitors of ERK *US6949580 (2005)*.
27. KenKnight, B.H., Warren, J.A., Hahn, S.J. Method for reducing restenosis in the presence of an intravascular stent *US6939345 (2005)*.
28. Knudson, M.B., Giese, W.L. Method to deliver blood from a heart chamber to a vessel *US6929011 (2005)*.
29. Knudson, M.B., Giese, W.L. Method for revascularizing a coronary vessel *US6913021 (2005)*.
30. Yon, S.A., Dobak, J.D.III, Kramer, H.W., Inderbitzen, R.S. Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing tissue protection *US6905494 (2005)*.
31. Antelman, D., Gregory, R.J., Wills, K.N. Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins *US6902731 (2005)*.
32. Honjo, T., Tashiro, K., Kobuke, K. Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide *US6900031 (2005)*.
33. Rychnovsky, S.J. Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy *US6887862 (2005)*.
34. Tang, Q., Maltais, F., Janetka, J.W., Hale, M.R. Pyrazole-derived kinase inhibitors and uses thereof *US6875789 (2005)*.
35. Miller, W.H., Gleason, J.G., Heerding, D., Samanen, J.M., Uzinskas, I.N., Manley, P.J. Vitronectin receptor antagonists *EP1061921A4 (2005)*.
36. Wohlfart, P., Suzuki, T., Dharanipragada, R.M., Safarova, A., Walser, A., Strobel, H. 4 - Fluoro-N-indan-2-yl benzamide for the stimulation of the expression of endothelial NO synthase and its use in cardiovascular diseases *NZ0527469A (2005)*.
37. Hewitt, W., Vasella, D.L., Webb, R.L. Synergistic combinations comprising a renin inhibitor for cardiovascular diseases *NZ0525795A (2005)*.
38. Zhang, H.-C., Maryanoff, B., Conway, B., White, K., Ye, H., Hecker, L.R., Mccomsey, D.F. Indazolyl-substituted pyrroline compounds as kinase inhibitors *NZ0526356A (2005)*.
39. Makino, S., Okuzumi, T., Yoshimura, T., Satake, Y., Suzuki, N., Izawa, H., Sagi, K., Chiba, A., Nakanishi, E., Murata, M., Tsuji, T. Phenylalanine derivatives useful as pharmaceutical agents *NZ0524122A (2005)*.
40. Vuligonda, V., Teng, M., Beard, R.L., Johnson, A.T., Lin, Y., Chandraratna, R.A. O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity *US6855832 (2005)*.
41. Bemis, G., Xie, X. Compositions useful as inhibitors of ERK *US6849267 (2005)*.
42. Dasseux, J.-L., Sekul, R., Büttner, K., Cornut, I., Metz, G., Dufourcq, J. Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders *US6844327 (2005)*.
43. Garvey, D.S., Letts, L.G., Lin, C.-E., Richardson, S.K., Wang, T. Nitrosated and nitrosylated taxanes, compositions and methods of use *US6869973 (2005)*.
44. Edwards, D.S., Liu, S. Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque *US6869590 (2005)*.
45. Brewer, R., Schreiner, G.F. Stents and intra-luminal prostheses containing MAP kinase inhibitors *WO05030091A3 (2005)*.
46. Zeldis, J.B. Drug-coated stents and methods of use therefore *US20050019366A1 (2005)*.
47. Brewer, R., Schreiner, G.F. Stents and intra-luminal prostheses containing MAP kinase inhibitors *WO05030091A2 (2005)*.
48. Ghosal, A., Tong, W., Chowdhury, S.K., Zbaida, S., Wirth, M.A., Alton, K.B., Patrick, J.E., Boyle, C.D., Stamford, A. Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction *WO05012303A1 (2005)*.
49. Day, D.E., Link, C.A. Anti-human vitronectin antibody and methods for making the same and *WO05007674A2 (2005)*.
50. Demopoulos, G.A., Pierce, P.A., Herz, J.M. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis *EP0910397B1 (2005)*.
51. Castro, D., Pacetti, S.D. Barriers for polymer-coated implantable medical devices and method for making the same *US6953560 (2005)*.
52. Schwartz, L.B., Weichselbaum, R.R., Roizman, B. Genetically engineered herpes virus for the treatment of cardiovascular disease *US6846670 (2005)*.
53. Zhang, N., Purchio, A., F. Methods and compositions for screening for angiogenesis modulating compounds *US6867348 (2005)*.
54. Varner, J.A. Methods for detecting and inhibiting angiogenesis *US6852318 (2005)*.
55. Carpenter, A.P. Jr. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent *US6838074 (2005)*.
56. Baird, A., Andreason, G. Variants of the angiogenic factor vascular endothelial cell growth factor:VEGF-A, and pharmaceutical use *NZ0505955A (2005)*.
57. Horres, R., Hoffmann, M., Faust, V., Hoffmann, E., Di Biase, D. Biocompatible, biostable coating of medical surfaces *US20050129731A1 (2005)*.

58. Nishiyama, H., Shudo, N., Tsuruzoe, N. Drug for inhibiting vascular intimal hyperplasia *WO05074938A1 (2005)*.
59. Horres, R., Linssen, M.K., Hoffmann, M., Hoffmann, E., Di Baise, D., Faust, V. Compounds and method for coating surfaces in a haemocompatible manner *US20050176678A1 (2005)*.
60. Harnek, J., Zouka, E.-V. Heparin stent *US20050171600A1 (2005)*.
61. Horres, R., Hoffmann, M., Hoffman, E., Di Biase, D., Faust, V. Coating of stents for preventing restenosis and *US20050060028A1 (2005)*.
62. Li, C., Wallace, S., Yu, D.-F., Yang, D.J. Water soluble paclitaxel derivatives *US6884817 (2005)*.
63. Donnelly, L.E., Barnes, P.J. Administration of resveratrol to treat inflammatory respiratory disorders. *US6878751 (2005)*.
64. Zvuloni, R., Bliweis, M., Schechter, D., Amir, U., McGlone, J. Cryoplasty apparatus and method *US6875209 (2005)*.
65. Gambale, R., Forcucci, S.J., Weiser, M.F., Forde, S. Implant and agent delivery device *US6855160 (2005)*.
66. Kopia, G.A., Llanos, G.H., Falotico, R.F. Drug Combinations useful for prevention of restenosis *EP1289576B1 (2005)*.
67. Fox, T.H., Crocker, I.R., Systems and methods for providing radiation therapy and catheter guides *EP1054616A4 (2005)*.
68. Kunz, L.L., Klein, R.A., Reno, J.M. Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis *EP1512398A1 (2005)*.